Adjuvant Transarterial Chemoembolization Plus Immunotherapy for Huge Hepatocellular Carcinoma: A Propensity Score Matching Cohort Study
Hongwei Huang,Wei Liao,Kaiyue Zhang,Hao Wang,Qi Cheng,Bin Mei
DOI: https://doi.org/10.2147/jhc.s455878
2024-04-08
Journal of Hepatocellular Carcinoma
Abstract:Hongwei Huang, &ast Wei Liao, &ast Kaiyue Zhang, Hao Wang, Qi Cheng, Bin Mei Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, People's Republic of China &astThese authors contributed equally to this work Correspondence: Bin Mei; Qi Cheng, Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1095 Jie Fang Avenue, Qiaokou, Wuhan, 430030, People's Republic of China, Email ; Purpose: The prognosis of patients with huge hepatocellular carcinoma (huge HCC, diameter ≥ 10 cm) is poor owing to the high early recurrence rate. This study aimed to explore the clinical value of postoperative adjuvant transarterial chemoembolization (PA-TACE) plus programmed cell death-1 (PD-1) inhibitors for huge HCC. Patients and Methods: Data from consecutive huge HCC patients treated with hepatectomy during June 2017 and July 2022 were retrospectively collected. Baseline differences were balanced between huge HCC patients who underwent PA-TACE with (AIT group) or without PD-1 inhibitors (AT group) by propensity-score matching (PSM). We compared recurrence-free survival (RFS), overall survival (OS) and recurrence patterns between the two groups. Independent risk factors for RFS and OS were confirmed by Cox regression analysis, and subgroup analysis was also conducted. Results: A total of 294 patients were enrolled, and 77 pairs of patients in the AIT and AT groups were matched by PSM. The 1-year and 2-year RFS were 49.9% and 35.7% in the AIT group compared to 24.7% and 15.5% in the AT group respectively (p< 0.001). The 1-year and 2-year OS were 83.6% and 66.9% in the AIT group compared to 50.6% and 36.8% in the AT group respectively (p< 0.001). There were no significant differences in recurrence patterns between the two groups. Multivariable analysis demonstrated that combined therapy of PA-TACE plus PD-1 inhibitors was a protective factor related to both RFS and OS. Conclusion: PA-TACE plus PD-1 inhibitors could improve survival outcomes for huge HCC patients. Keywords: hepatocellular carcinoma, postoperative adjuvant therapy, programmed cell death-1 inhibitors, transarterial chemoembolization, early recurrence Hepatocellular carcinoma (HCC) is the most common type of liver cancer, accounting for 75–86% of cases. 1 Many HCC patients were diagnosed with huge sizes (exceeding 10 cm in diameter) owing to insidious symptoms and lacking of well-organized screening programs. 2,3 Although hepatectomy demonstrated quite high feasibility and cost-effectiveness and was the only curative treatment for huge HCC, the oncological outcomes were still poor for early recurrence following surgery. 4,5 The recurrence rates remained as high as 32.1–54% at 1 year and 57–70% at 3 years. 2,3,6,7 Therefore, postoperative adjuvant treatment is necessary to reduce early recurrence rate and improve oncological prognosis for patients with huge HCC. Postoperative adjuvant treatment includes locoregional treatments such as transarterial chemoembolization (TACE), hepatic artery infusion chemotherapy, radiotherapy, and systemic therapy such as antiviral treatment, tyrosine kinase inhibitors (TKIs), and immune checkpoint inhibitors (ICIs). 8–12 Up to date, postoperative adjuvant TACE (PA-TACE) has demonstrated its importance in reducing recurrence rate, improving recurrence-free survival (RFS) and overall survival (OS) for HCC patients with high recurrence risks, including huge HCC. 8,13,14 Therefore, PA-TACE was recommended in guidelines of China. However, the effect of PA-TACE is still unsatisfactory. TACE, as a kind of locoregional treatment, can be used in combination with systemic therapy to further improve oncological prognosis of HCC. ICIs are being explored as postoperative adjuvant treatment for HCC in several Phase III clinical trials, such as EMERALD-2, KEYNOTE-937, IMbrave 050, CheckMate 9DX. Recently, ICIs were recommended as adjuvant therapy for patients with HCC by the latest guidelines of American Association for the Study of Liver Diseases (AASLD) according to the interim results of IMbrave 050 which showed that adjuvant atezolizumab plus bevacizumab was associated with significantly improved RFS compared with active surveillance (1-year RFS, 78% vs 65%). 15,16 However, to the best of our knowledge, there is still no study about PA-TACE plus adjuvant immunotherapy for huge HCC. In this study, two cohorts were established according to different postoperative adjuvant treatments. All included patients with huge tumor underwent R0 hepatectomy. The short-term oncological outcomes of the two methods were compared, -Abstract Truncated-
oncology